Condition: Biliary Tract Neoplasms Immunotherapy · Sponsor: Peking Union Medical College Hospital
Explore the impact of the first-line application of Pembrolizumab with or without Lenvatinib or chemotherapy, on the survival, disease progression, and drug safety of patients with advanced biliary tract cancers
This description comes directly from the study's public registry record.
haitao Zhao, Ph.D · +861069156042 · zhaoht@pumch.cn
Always discuss trial participation with your own doctor first.
| Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH) | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06230471